Healthcare Asia Magazine on MSN1d
Here’s what’s driving the multiple myeloma marketAdvancements in newer therapies are expected to drive its expansion. A rise in incident cases, expanded use of existing ...
Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to organ dysfunction and, eventually, death. There were more than 33,000 ...
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...
In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...
Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for cutting-edge treatment. The CAR T-cell therapy involves the col ...
During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...
The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback